Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Global Blood Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common…
Celgene $8.0 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion…
Aimmune Therapeutics, Inc. $183.9 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies,…
Atara Biotherapeutics, Inc. $207 Million Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $207 million SEC-registered follow-on offering of…
Natera, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of 10,000,000…
Davis Polk Advises Capio AB on Its SEK2.5 Billion (US$300 Million) Initial Public Offering
Davis Polk advised Capio AB (publ) on its initial public offering and listing of shares on NASDAQ Stockholm. Assuming full…
Hologic, Inc. $1 Billion Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $1…
Impax Laboratories, Inc. $600 Million Convertible Senior Notes Offering
Davis Polk advised the sole structuring advisor and sole bookrunner in a Rule 144A offering by Impax Laboratories, Inc. of…
Cynapsus Therapeutics Inc. $72.5 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common…
Biotie Therapies Corp. Initial Public Offering
Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American…